Catalog No.
Product Name
Application
Product Information
Citations
-
BTK Inhibitor
BTK-IN-10 is a highly potent Bruton’s Tyrosine Kinase (BTK) inhibitor, exhibiting IC50 values of less than 5 nM against both wild-type BTK and the C481S mutant variant. This compound is ideal for studying BTK signaling pathways and evaluating therapeutic strategies in hematological malignancies. Its efficacy in inhibiting BTK makes it a valuable tool for researchers investigating the role of BTK in immune regulation and cancer biology. -
Pan-BTK Inhibitor
GNE-431 is a potent, selective, noncovalent pan-BTK inhibitor that targets various BTK mutants, including C481R, T474I, and T474Ms. It demonstrates significant biological activity with an IC50 of 3.2 nM against wild-type BTK and 2.5 nM against the C481S mutant. GNE-431 is a valuable tool for research into hematological disorders and autoimmune diseases, providing insights into the modulation of B-cell signaling pathways. -
BTK Inhibitor
BTK-IN-21 is a potent Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 33 nM. It exhibits significant inhibitory effects on BTK activity, making it a valuable tool for research applications related to cancer and autoimmune diseases. This compound enables the exploration of BTK signaling pathways and supports the development of targeted therapies in these areas. -
Btk Inhibitor
BTK Inhibitor 19 is a highly selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), with an IC50 value of 2.7 nM. This compound effectively modulates BTK activity, playing a crucial role in pathways associated with B cell receptor signaling. It is particularly valuable in research applications focused on B cell malignancies and autoimmune diseases, facilitating the exploration of therapeutic strategies targeting BTK. -
Btk Inhibitor
Civorebrutinib is a selective inhibitor of Bruton's tyrosine kinase (Btk), which plays a critical role in B cell receptor signaling. This compound exhibits significant antineoplastic activity, making it a valuable tool for research into B cell malignancies and related disorders. Its ability to modulate B cell function positions Civorebrutinib as a candidate for studies examining targeted therapies in hematological cancers. -
BTK Inhibitor
RN941 is a potent Bruton's tyrosine kinase (BTK) inhibitor, targeting the BTK signaling pathway. It exhibits significant biological activity in modulating B-cell signaling, making it a valuable tool in the study of rheumatoid arthritis and B-cell malignancies. RN941 is suitable for research applications involving disease mechanisms and therapeutic strategies in these conditions. -
BTK Mutant Inhibitor
AMX5160 is an orally active Bruton's tyrosine kinase (BTK) inhibitor, specifically targeting the mutant BTKC481S with an IC50 of 0.98 nM. This reagent is useful for investigating the role of BTK in various malignancies, including leukemia and lymphoma, as well as in research related to multiple sclerosis and other autoimmune disorders. -
Topoisomerase I Inhibitor
Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I, a key enzyme involved in DNA replication and repair. This compound disrupts the enzyme's catalytic activity, leading to the accumulation of DNA damage and ultimately inducing apoptosis in cancer cells. Topoisomerase I inhibitor 11 is primarily utilized in cancer research, particularly for studying mechanisms of drug resistance and the therapeutic potential of targeting Topoisomerase I in various malignancies. -
BTK/IKZF1/3 PROTAC Ligand
BTK/IKZF1/3 ligand 1 is a PROTAC ligand targeting Bruton's tyrosine kinase (BTK) and the Ikaros family zinc finger proteins (IKZF1/3). This compound can be conjugated with E3 ligase ligands and linkers to produce PROTAC BTK/IKZF1/3 Degrader-1, facilitating targeted protein degradation. It is valuable for cancer research, supporting investigations into therapeutic strategies aimed at modulating BTK and IKZF1/3 activity in malignant cells. -
PF-06250112 Racemate
(Rac)-PF-06250112 is a racemic mixture of PF-06250112, a highly selective and orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates potent inhibitory activity against BTK as well as BMX nonreceptor tyrosine kinase and TEC. Its selectivity and efficacy make it a valuable tool for research applications focused on B cell malignancies and other diseases associated with aberrant BTK signaling. -
BTK Inhibitor
BTK-IN-8 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), exhibiting a binding affinity with an IC50 of 0.22 nM and a Kd of 0.91 nM. This compound demonstrates significant cellular activity against whole blood CD69, with an IC50 of 0.029 µM. BTK-IN-8 is primarily used in research focused on hematological malignancies and autoimmune disorders, providing insights into BTK-mediated signaling pathways. -
BTK PROTAC Degrader
PROTAC BTK Degrader-12 is a PROTAC (Proteolysis Targeting Chimera) designed to selectively degrade Bruton's tyrosine kinase (BTK). It facilitates the targeted ubiquitination and subsequent proteasomal degradation of BTK, resulting in diminished signaling pathways associated with B-cell malignancies and autoimmune disorders. This compound serves as a valuable tool in research investigating BTK's role in disease mechanisms and therapeutic interventions. -
Btk Inhibitor
RN983 is a highly selective inhibitor of Bruton's tyrosine kinase (Btk), demonstrating potent inhibition of immunoglobulin G (IgG) production in B-cells with an IC50 of 2.5 nM, and prostaglandin D2 (PGD2) production in mast cells with an IC50 of 8.3 nM. This compound serves as a valuable tool for investigating the roles of Btk in B-cell signaling and mast cell activation, making it relevant in the study of asthma and other allergic diseases. -
BTK Inhibitor
BTK-IN-36 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, exhibiting an IC50 of 0.5 nM. This compound effectively inhibits BTK signaling pathways, which are crucial for B-cell receptor signaling and have implications in various cancers. BTK-IN-36 is applicable in cancer research, particularly in studies exploring targeted therapies for B-cell malignancies. -
RET Inhibitor
RET-IN-14 is a highly selective RET inhibitor that demonstrates potent inhibition with IC50 values of less than 0.51 nM for wild-type RET and varying nanomolar activity against RET mutations (G810R and V804M) as well as BTK and its C481S mutant. Its exceptional efficacy positions RET-IN-14 as a valuable tool for investigating RET-driven tumors and exploring therapeutic strategies in cancer research. -
BTK Inhibitor
BTK-IN-15 is a highly potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 0.7 nM. This compound demonstrates exceptional selectivity for BTK and displays significant antitumor activity. Additionally, BTK-IN-15 is known to induce apoptosis, making it a valuable tool for research in cancer biology and the development of targeted therapies. -
BTK Inhibitor
VA5 is a potent Bruton’s tyrosine kinase (BTK) inhibitor, designed to selectively inhibit BTK activity. This compound plays a crucial role in modulating B-cell signaling pathways and has potential applications in studying various diseases associated with dysregulated BTK activity, including certain hematological malignancies and autoimmune disorders. VA5 serves as a valuable tool in preclinical research to further investigate the therapeutic potential of targeting BTK. -
BTK Degrader
PROTAC BTK Degrader-11 is a potent PROTAC designed to selectively degrade Bruton's tyrosine kinase (BTK), exhibiting a DC50 of 1.7 nM. This compound facilitates targeted protein degradation, offering significant potential in cancer research applications by modulating BTK-related pathways. The structure includes a target protein ligand, a linker, and an E3 ligase component, allowing for effective engagement of the ubiquitin-proteasome system. -
BTK Inhibitor
BTK-IN-38 is a potent inhibitor of Bruton's tyrosine kinase (BTK). It effectively inhibits the proliferation of DOHH2 and BT474 cancer cell lines, exhibiting IC50 values of 114 nM and 340 nM, respectively. This compound is of particular interest in research applications targeting B-cell malignancies and related signaling pathways. -
BTK PROTAC Degrader
TQ-3959 is an orally bioavailable BTK PROTAC degrader that demonstrates a DC50 of 14.6 nM. It exhibits potent antiproliferative effects on both wild-type BTK and the C481S mutant BTK cell lines. In vivo, TQ-3959 effectively inhibits tumor growth in female NOD-SCID mice bearing TMD-8 xenografts. This compound is valuable for investigating B-cell malignancies, including lymphoma. -
BTK Inhibitor
BTK-IN-23 is a selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 12.8 nM. This compound also exhibits inhibitory effects on BMX and BLK, with IC50 values of 5.7 nM and 35.6 nM, respectively. BTK-IN-23 demonstrates enhanced kinase selectivity compared to Ibrutinib, making it a valuable tool for research in cancer and autoimmune disease therapies, particularly in studies focusing on B-cell signaling pathways. -
BTK Inhibitor
BTK-IN-43 is a selective inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 value of 21.6 nM. This compound is capable of oral administration and exhibits potent activity against BTK-mediated signaling pathways. It is primarily utilized in research applications focused on hematological malignancies and immune disorders driven by aberrant BTK activity. -
BTK Degrader
BTK Degrader-2 is a potent dual-functional agent designed to degrade Bruton's tyrosine kinase (BTK) via the ubiquitin-proteasome pathway. This compound is valuable for investigating B-cell-related disorders by providing insights into BTK's role in cellular processes and disease mechanisms. Its application in research can enhance the understanding of therapeutic strategies targeting B-cell malignancies and other related diseases. -
BTK Inhibitor
HZ-A-005 is a potent and selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), a critical regulator in B cell receptor signaling. This compound demonstrates significant anti-tumor activity, effectively reducing tumor growth in xenograft mouse models. HZ-A-005 is valuable for research applications focused on B cell malignancies and the study of BTK's role in various signaling pathways. -
Btk Inhibitor
BTK-IN-32 is a selective Bruton’s tyrosine kinase (BTK) inhibitor that effectively modulates BTK activity. It uniquely activates both full-length BTK and smaller multidomain fragments, rather than solely targeting the isolated kinase domain. This compound is useful in research applications focused on B-cell signaling pathways and the development of therapies for related hematological malignancies. -
Btk Degrader
BTK Ligand 1 is a selective ligand for Bruton’s tyrosine kinase (Btk) that facilitates targeted protein degradation via a PROTAC (proteolysis-targeting chimera) approach. By linking with an E3 ligase ligand through a PROTAC linker, this compound enables the targeted degradation of Btk. BTK Ligand 1 is valuable for researching chronic lymphocytic leukemia (CLL) and other B-cell malignancies, providing insights into the therapeutic potential of Btk inhibition in oncology. -
BTK Inhibitor
BTK Inhibitor 20 is a highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), exhibiting an IC50 value of 8 nM. This compound effectively modulates the BTK signaling pathway, playing a critical role in B-cell receptor signaling and related processes. It is valuable for research focused on B-cell malignancies, autoimmune diseases, and other conditions where BTK activity is implicated. -
BTK Inhibitor
BTK-IN-25 is a highly potent inhibitor of Bruton’s tyrosine kinase (BTK), demonstrating an IC50 of 0.77 nM against the BTK(C481S) mutant and 1 nM in DOHH2 cells. This compound is valuable for exploring BTK-related signaling pathways and potential therapeutic interventions in B-cell malignancies. Its selective inhibition of BTK makes it a useful tool for research applications focused on the modulation of immune responses and the development of targeted cancer therapies. -
BTK Inhibitor
BTK-IN-12 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, with IC50 values of 1.2 nM for wild-type BTK and 0.8 nM for the mutated BTK (C481S). This compound selectively targets BTK, a key regulator in B-cell receptor signaling, making it valuable for research in hematological malignancies and autoimmune disorders. BTK-IN-12 can facilitate the study of therapeutic approaches for conditions associated with dysregulated B-cell activity. -
BTK Inhibitor
ABBV-992 is a potent and selective Bruton's Tyrosine Kinase (BTK) inhibitor. It demonstrates significant inhibitory activity, making it a valuable tool for studying various hematological malignancies. This compound is primarily utilized in cancer research to investigate BTK signaling pathways and their roles in tumor progression and survival. -
BTK/IKZF1/3 PROTAC Degrader
PROTAC BTK/IKZF1/3 Degrader-1 is a selective and orally bioavailable degrader targeting BTK, IKZF1, and IKZF3 through the PROTAC mechanism. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research, particularly in the context of lymphoma. Its unique mechanism of action allows for the targeted degradation of specific oncogenic proteins, facilitating studies in therapeutic strategies and disease mechanisms. -
PROTAC BTK Degrader
PROTAC BTK Degrader-4 is a highly effective PROTAC designed to selectively degrade Bruton's tyrosine kinase (BTK) with a DC50 of less than 100 nM. This compound demonstrates minimal immunomodulatory imide drug (IMiD) activity, with a DC50 of 0.345 μM and a maximum degradation rate of 27.4%. PROTAC BTK Degrader-4 is suitable for investigating various pathologies, including cancers, autoimmune disorders, and inflammatory diseases associated with BTK dysregulation. -
BTK Inhibitor
(R)-Acalabrutinib is a specific inhibitor of Bruton’s tyrosine kinase (BTK), a critical protein involved in B-cell receptor signaling. This compound serves as a valuable tool for research applications in hematological malignancies, particularly in the study of B-cell functions and the development of targeted therapies for conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its high selectivity for BTK allows for detailed investigations into BTK-mediated pathways and potential therapeutic interventions. -
BTK Inhibitor
BTK-IN-19 is a reversible Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of less than 0.001 μM. This compound demonstrates potent inhibitory activity against BTK, making it a valuable tool for studying B-cell signaling pathways. BTK-IN-19 is applicable in research focused on various hematological malignancies and autoimmune diseases, contributing to the understanding of therapeutic strategies targeting BTK. -
BTK Inhibitor
BTK-IN-16 is a dual inhibitor targeting Bruton’s tyrosine kinase (BTK), specifically effective against both wild type and the C481S mutant, with IC50 values of 5.1 μM and 4.1 μM, respectively. This compound is crucial for research into autoimmune diseases and chronic lymphocytic leukemia, where BTK plays a significant role in disease progression. Its ability to inhibit both forms of BTK makes BTK-IN-16 a valuable tool for studying therapeutic strategies in these conditions. -
BTK PROTAC Degrader
PROTAC BTK Degrader-3 is a selective degrader targeting Bruton's tyrosine kinase (BTK) with a DC50 value of 10.9 nM for BTK degradation in Mino cells. This compound demonstrates significant biological activity and is applicable in research focusing on B-cell malignancies, particularly chronic lymphoid malignancies. Its mechanism of action offers potential pathways for therapeutic intervention in relevant disease models. -
Btk Inhibitor
BTK-IN-3 is a selective inhibitor of Bruton's tyrosine kinase (BTK), a critical component in B-cell receptor signaling. This compound demonstrates significant biological activity by inhibiting BTK-mediated pathways, which are often implicated in various hematological malignancies. BTK-IN-3 is therefore utilized in research applications focused on cancer biology, particularly in the investigation of B-cell cancers and autoimmune disorders. -
Btk Inhibitor
Ibrutinib dimer is a dimeric form of Ibrutinib, a selective and irreversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 0.5 nM. This compound serves as a valuable tool for studying Btk-mediated signaling pathways and its implications in various hematological malignancies. Researchers can utilize Ibrutinib dimer to investigate the effects of Btk inhibition in cellular models and to explore its potential therapeutic applications in cancer research. -
Btk Inhibitor
(Rac)-IBT6A hydrochloride is a racemic mixture of IBT6A, a byproduct of Ibrutinib. This compound acts as a selective, irreversible Bruton's tyrosine kinase (Btk) inhibitor with an IC50 of 0.5 nM, making it useful for studying Btk-mediated signaling pathways. It serves as a valuable reagent in the synthesis of Ibrutinib derivatives and adducts, facilitating research into therapeutic strategies for diseases such as B-cell malignancies. -
BTK PROTAC Degrader
PROTAC BTK Degrader-14 is a targeted protein degrader that specifically degrades Bruton's tyrosine kinase (BTK) through the PROTAC mechanism of action. This compound is significant in cancer research, particularly for studies focused on malignancies where BTK plays a crucial role in signaling pathways. Its ability to effectively modulate BTK levels can provide insights into therapeutic strategies and disease mechanisms involving this key protein. -
BTK Ligand
BTK Ligand 9 is a selective ligand for Bruton's tyrosine kinase (BTK), a critical regulator in B cell receptor signaling. This compound facilitates the development of PROTACs, specifically PROTAC DD-03-171, which are utilized in targeted protein degradation studies. Research applications include investigating the role of BTK in various hematological malignancies and exploring therapeutic strategies for B cell-related diseases. -
BTK Inhibitor
(R,R)-Birelentinib is a potent Bruton's tyrosine kinase (BTK) inhibitor, achieving IC50 values of 0.7 nM for wild-type BTK and 0.86 nM for the C481S mutant. This compound effectively inhibits the self-phosphorylation of BTK, with an IC50 of 24.3 nM. (R,R)-Birelentinib demonstrates significant anti-proliferative effects against wild-type and C481S mutant HEK293 cells, making it valuable for research into drug-resistant B-cell malignancies. -
BTK Degrader Mediate
BTK Degrader-1 Intermediate is a key precursor in the synthesis of BTK Degrader-1, a potent molecule targeting Bruton's tyrosine kinase (BTK). This compound serves as an essential building block for developing antibody-drug conjugates (ADCs), enabling targeted therapy for diseases associated with BTK dysregulation. Researchers utilize BTK Degrader-1 Intermediate in drug development processes to explore innovative treatment strategies in oncology and immunology. -
BTK Inhibitor
CGI 560 is a potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 400 nM. This compound plays a significant role in the modulation of B-cell receptor signaling pathways, making it a valuable tool for research in hematological malignancies and autoimmune diseases. Its ability to selectively inhibit BTK can aid in elucidating the mechanistic underpinnings of various B-cell-related disorders. -
PROTAC ALK Degrader
SIAIS001 is a potent PROTAC degrader targeting anaplastic lymphoma kinase (ALK) with a DC50 of 3.9 nM. This compound induces G1/S phase cell cycle arrest and effectively inhibits the proliferation of SR cells with an IC50 of 0.9 nM. SIAIS001 is suitable for research in non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs). -
NPM-ALK PROTAC Degrader
MS99-β-Gal is a galactose-modified PROTAC degrader targeting the NPM-ALK fusion protein. This compound is selectively hydrolyzed by SA-β-gal and esterase in senescent cancer cells, allowing the release of MS99, which effectively degrades the NPM-ALK protein. MS99-β-Gal demonstrates an IC50 of 454.8 nM in aging Karpas 299 cells, showing improved potency compared to normal Karpas 299 cells with an IC50 of 2.162 μM. This reagent is valuable for cancer research, particularly in studies focused on targeted protein degradation. -
ALKBH5 Inhibitor
ALKBH5-IN-3 is a selective inhibitor of the ALKBH5 enzyme, exhibiting an IC50 of 0.021 μM. This compound effectively stabilizes ALKBH5 in HepG2 cells, resulting in an elevated level of m6A in intact cells. ALKBH5-IN-3 serves as a valuable chemical probe for investigating the biological functions of ALKBH5, with significant applications in cancer research. -
ALK Inhibitor
CPD-1224 is a potent ALK inhibitor that specifically targets the EML4-ALK oncogenic fusion protein. This compound promotes the degradation of both ALK and its mutant forms, including L1196M and G1202R. CPD-1224 demonstrates significant potential in slowing tumor growth, making it a valuable reagent for cancer research and therapeutic development focused on ALK-driven malignancies. -
ALK Inhibitor
Zotizalkib is a potent and selective inhibitor of anaplastic lymphoma kinase (ALK) with a low IC50 of 1.4 nM for wild-type ALK and 0.3 nM for key ALK-resistant mutations such as G1202R and L1196M. This CNS-penetrant compound demonstrates significant antitumor activity, making it valuable for research in cancer biology and treatment strategies for ALK-driven tumors. Its oral bioavailability and ability to target resistant ALK mutations further enhance its potential in therapeutic applications. -
ALK1/2 Inhibitor
M4K2234 is a potent and selective inhibitor of ALK1 and ALK2, with IC50 values of 7 nM and 14 nM, respectively. This compound effectively disrupts BMP signaling by inhibiting the phosphorylation of SMAD1/5/8, thereby reducing BMP7-stimulated reporter activity (IC50 = 16 nM). M4K2234 is suitable for studying ALK1/2-mediated biological pathways and investigating diseases such as diffuse midline glioma (DMG) and fibrodysplasia ossificans progressiva (FOP).
